Home
MRK
MRK News

Latest Merck & Company Inc. (new) (MRK) News on September 3, 2025

More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.

Barrons.com

21 hours ago

More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Benzinga

a day ago

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck (MRK) Announces Positive Results From Phase 3 CORALreef Lipids Trial

Simply Wall St.

a day ago

Merck (MRK) Announces Positive Results From Phase 3 CORALreef Lipids Trial

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

Motley Fool

a day ago

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

Morningstar Research

a day ago

Analyst Report: Merck & Co., Inc.

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

Zacks

a day ago

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

MT Newswires

a day ago

Market Chatter: Merck Selling Bonds to Help Fund Verona Acquisition

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

Zacks

a day ago

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

MT Newswires

a day ago

Merck Says Enlicitide Met Primary and Secondary Endpoints in Hypercholesterolemia Study

MT Newswires

a day ago

Merck's Verquvo Fails to Meet Primary Endpoint in Phase 3 Victor Trial

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

Business Wire

a day ago

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Business Wire

a day ago

Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028

Insider Monkey

a day ago

Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028

NVIDIA Corporation (NVDA): Take A Look At Jim Cramer’s 1,000+ Words About The Stock After Q2 Earnings

Insider Monkey

3 days ago

NVIDIA Corporation (NVDA): Take A Look At Jim Cramer’s 1,000+ Words About The Stock After Q2 Earnings

Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial

Insider Monkey

4 days ago

Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial

How Much Would It Take To Earn $100 A Month From Merck Stock

Benzinga

4 days ago

How Much Would It Take To Earn $100 A Month From Merck Stock

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

Business Wire

5 days ago

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

Is Merck Stock Outperforming the Dow?

Barchart

5 days ago

Is Merck Stock Outperforming the Dow?

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

Zacks

5 days ago

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

MT Newswires

5 days ago

DBS Bank Adjusts Merck Price Target to $100 From $96, Maintains Buy Rating

Here’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition

Insider Monkey

6 days ago

Here’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition

Veeva Systems (VEEV) Reports Strong Q2 Earnings With US$789 Million Revenue

Simply Wall St.

6 days ago

Veeva Systems (VEEV) Reports Strong Q2 Earnings With US$789 Million Revenue

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

Zacks

6 days ago

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Zacks

6 days ago

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Zacks

6 days ago

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

Zacks

6 days ago

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

Business Wire

6 days ago

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances

Insider Monkey

6 days ago

Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances

Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine

Insider Monkey

6 days ago

Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine

ACCESS Newswire

7 days ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

MT Newswires

7 days ago

Merck's Phase 3 Trial for Metastatic Breast Cancer Treatment Doses First Patient

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy

Business Wire

7 days ago

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

GlobeNewswire

7 days ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

Rising as One, Shining as Many - Global New Material International opens a new chapter for Zhejiang entrepreneurs going global on 29 August 2025

GlobeNewswire

8 days ago

Rising as One, Shining as Many - Global New Material International opens a new chapter for Zhejiang entrepreneurs going global on 29 August 2025

Argus Research

8 days ago

The Argus High-Yield Model Portfolio

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

Zacks

8 days ago

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

IOVA Stock Drops 6% on $350M Common Stock Offering

Zacks

8 days ago

IOVA Stock Drops 6% on $350M Common Stock Offering

Dow Loses About 350 Points After Record-Breaking Run

The Wall Street Journal

9 days ago

Dow Loses About 350 Points After Record-Breaking Run

Stock Market Today: Dow Drops, Apple Firm Despite Musk Threat; Cathie Wood Loads Up On This Stock (Live Coverage)

Investor's Business Daily

9 days ago

Stock Market Today: Dow Drops, Apple Firm Despite Musk Threat; Cathie Wood Loads Up On This Stock (Live Coverage)

Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress

Simply Wall St.

9 days ago

Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

Zacks

9 days ago

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

GlobeNewswire

9 days ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Argus Research

9 days ago

Analyst Report: Merck & Co Inc

Argus Research

9 days ago

Market Digest: EOG, MKTX, MRK, ZBH, RIO, ZM

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Business Wire

9 days ago

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Merck (MRK): Valuation Update Following FDA Breakthrough in Oncology and New Approvals

Simply Wall St.

9 days ago

Merck (MRK): Valuation Update Following FDA Breakthrough in Oncology and New Approvals

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

PR Newswire

10 days ago

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

Zacks

12 days ago

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

FDA Breakthrough for Lung Cancer Drug Might Change the Case For Investing In Merck (MRK)

Simply Wall St.

12 days ago

FDA Breakthrough for Lung Cancer Drug Might Change the Case For Investing In Merck (MRK)

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

13 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

13 days ago

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Leaders Come Together to Advance the Industry at Veeva Summit

PR Newswire

13 days ago

Leaders Come Together to Advance the Industry at Veeva Summit

The biggest Big Pharma losers in the first half of 2025

Pharma Voice

13 days ago

The biggest Big Pharma losers in the first half of 2025

MT Newswires

14 days ago

Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says

Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation

Simply Wall St.

15 days ago

Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Zacks

15 days ago

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Zacks

15 days ago

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

Zacks

15 days ago

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

Business Wire

15 days ago

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

Merck announces EC approval of Ogsiveo for desmoid tumours

Pharmaceutical Technology

15 days ago

Merck announces EC approval of Ogsiveo for desmoid tumours

A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?

Barrons.com

16 days ago

A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?

Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

Insider Monkey

16 days ago

Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline

GuruFocus.com

16 days ago

Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Zacks

16 days ago

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

GlobeNewswire

16 days ago

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

MT Newswires

16 days ago

Merck-Daiichi Sankyo Potential Small Lung Cancer Treatment Receives FDA Breakthrough Designation

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Business Wire

16 days ago

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Pharma Voice

16 days ago

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

Insider Monkey

17 days ago

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

Insider Monkey

17 days ago

OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

Insider Monkey

18 days ago

Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

2 Top Dividend Stocks to Buy on the Dip

Motley Fool

18 days ago

2 Top Dividend Stocks to Buy on the Dip

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

Insider Monkey

19 days ago

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

Insider Monkey

19 days ago

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey

Zacks

19 days ago

The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

Zacks

19 days ago

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers

StockStory

20 days ago

Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers

Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers

Benzinga

20 days ago

Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers

Top Analyst Reports for Merck, Palo Alto & Freeport

Zacks

20 days ago

Top Analyst Reports for Merck, Palo Alto & Freeport

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Zacks

20 days ago

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

China pharma firms turn to local reagent suppliers to cut costs and delivery times

Reuters

21 days ago

China pharma firms turn to local reagent suppliers to cut costs and delivery times

3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever

Motley Fool

21 days ago

3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Zacks

21 days ago

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

GlobeNewswire

21 days ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

Zacks

21 days ago

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge

GlobeNewswire

21 days ago

Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge

MT Newswires

21 days ago

Merck Gets Keytruda Approval for Head and Neck Cancer in Canada

Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

CNW Group

21 days ago

Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation

GlobeNewswire

21 days ago

Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation

MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period

StockStory

22 days ago

MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period

5 Must-Read Analyst Questions From Merck’s Q2 Earnings Call

StockStory

22 days ago

5 Must-Read Analyst Questions From Merck’s Q2 Earnings Call

Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment

Simply Wall St.

22 days ago

Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment

Mutual Funds Can't Get Enough Nvidia Stock, Google. Here's Why.

Investor's Business Daily

22 days ago

Mutual Funds Can't Get Enough Nvidia Stock, Google. Here's Why.

DraftKings price target raised to $55 from $45 at Argus

TipRanks

22 days ago

DraftKings price target raised to $55 from $45 at Argus

ACHR: Archer Aviation Stock Tumbles as Q2 Loss Nearly Doubles

GuruFocus.com

22 days ago

ACHR: Archer Aviation Stock Tumbles as Q2 Loss Nearly Doubles

Defense Stock Breaks Out After Earnings, Analyst Upgrade

Investor's Business Daily

22 days ago

Defense Stock Breaks Out After Earnings, Analyst Upgrade

Core CPI Inflation Tops 3%, But It Won't Stop The Fed; S&P 500 Rises (Live Coverage)

Investor's Business Daily

22 days ago

Core CPI Inflation Tops 3%, But It Won't Stop The Fed; S&P 500 Rises (Live Coverage)

Argus cuts Arthur J. Gallagher target, sees buying opportunity on selloff

TipRanks

22 days ago

Argus cuts Arthur J. Gallagher target, sees buying opportunity on selloff

Verantos Named to Inc. 5000 List for the Fourth Consecutive Year

Business Wire

22 days ago

Verantos Named to Inc. 5000 List for the Fourth Consecutive Year

Shrewsbury School UK Opens Its Inaugural South-Asian Campus in India

Business Wire

22 days ago

Shrewsbury School UK Opens Its Inaugural South-Asian Campus in India

Share on Social Networks: